BioNTech, DualityBio to Develop Antibody-Drug Conjugate Therapeutics for Solid Tumors

 

• BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers
• Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potential
• DualityBio receives upfront payments totaling $170 million, and will be eligible to receive development, regulatory and commercial milestone payments potentially totaling over $1.5 billion as well as single-digit to double-digit tiered royalties on potential future product sales

https://www.biospace.com/article/releases/biontech-and-dualitybio-form-global-strategic-partnership-to-accelerate-development-of-differentiated-antibody-drug-conjugate-therapeutics-for-solid-tumors/